Arena Pharmaceuticals, Inc. reported that sheer data from a clinical trial evaluating the abuse abeyant of lorcaserin were presented in a poster session at the 48th Annual Meeting of the stars and stripes College of Neuropsychopharmacology. Data from the trial demonstrate that the risk for abuse customer's broker person with lorcaserin is very low.

More: - From the site